LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer.
Ning S, Armstrong CM, Xing E, Leslie AR, Gao RY, Sharifi M, Schaaf ZA, Lou W, Han X, Xu DH, Yang R, Cheng J, Mohammed S, Mitsiades N, Liu C, Lombard AP, Wu CY, Cheng X, Li PK, Gao AC.
Ning S, et al. Among authors: cheng j, cheng x.
Cancer Res. 2024 Aug 1. doi: 10.1158/0008-5472.CAN-24-0440. Online ahead of print.
Cancer Res. 2024.
PMID: 39088701